ViaCyte scores $5.4 mln
ViaCyte said Friday that it has raised $5.4 million by selling Series C-1 Preferred Stock. The investors were not named. Headquartered in San Diego, ViaCyte develops cell therapy that treats diabetes.
8 August 2014•2 mins read
